ADMA Biologics

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was accepted by the FDA on September 18, 2015. The company has received U.S. Patent 9,107,906.
Company Growth (employees)
Type
Public
HQ
Ramsey, US
Founded
2004
Size (employees)
92 (est)
ADMA Biologics was founded in 2004 and is headquartered in Ramsey, US

Key People at ADMA Biologics

Bryant E. Fong

Bryant E. Fong

Director
Dov Goldstein

Dov Goldstein

Director
James Mond

James Mond

Chief Scientific and Medical Officer
Brian Lenz

Brian Lenz

Vice President, Chief Financial Officer
Eric I. Richman

Eric I. Richman

Director & Chairperson
Jerrold B. Grossman

Jerrold B. Grossman

Founder and Vice Chairman

ADMA Biologics Office Locations

ADMA Biologics has an office in Ramsey
Ramsey, US (HQ)
465 NJ-17

ADMA Biologics Data and Metrics

ADMA Biologics Financial Metrics

ADMA Biologics's revenue was reported to be $2.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

2.6 m

Net income (Q1, 2017)

(6.5 m)

EBIT (Q1, 2017)

(5.9 m)

Market capitalization (22-Aug-2017)

47.5 m

Cash (31-Mar-2017)

8.5 m
ADMA Biologics's current market capitalization is $47.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

3.1 m5.9 m7.2 m10.7 m

Revenue growth, %

93%21%49%

R&D expense

7.7 m

General and administrative expense

8.5 m

Operating expense total

16.2 m

EBIT

(15 m)(16 m)(15.5 m)(17.3 m)

EBIT margin, %

(490%)(271%)(216%)(163%)

Interest expense

618.2 k1.3 m1.8 m2.2 m

Interest income

7.6 k14.2 k37.8 k50.3 k

Pre tax profit

(15.5 m)(17.4 m)(18 m)

Net Income

(15.5 m)(16.8 m)(18 m)(19.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.5 m1.4 m1.5 m1.3 m1.9 m2.1 m2.3 m2.9 m2.6 m

R&D expense

1.8 m1.5 m1.4 m1.5 m2.1 m2 m3.4 m1.7 m1.2 m

General and administrative expense

1.5 m1 m1.3 m1.4 m2.1 m1.7 m1.7 m1.8 m4.3 m

Operating expense total

3.3 m2.5 m2.7 m2.9 m4.2 m3.7 m5.1 m3.5 m5.5 m

EBIT

(3.6 m)(3 m)(3.2 m)(3.5 m)(4.7 m)(4.2 m)(5.5 m)(3.7 m)(5.9 m)

EBIT margin, %

(239%)(222%)(213%)(268%)(252%)(196%)(242%)(127%)(226%)

Interest expense

342.8 k335.3 k476 k453.4 k449.3 k467.4 k538 k606 k618.5 k

Interest income

3.6 k3.5 k5 k9.8 k11.1 k13.5 k12 k11.6 k18.6 k

Net Income

(4 m)(3.4 m)(3.6 m)(4.7 m)(5.1 m)(4.6 m)(6 m)(4.3 m)(6.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

26.1 m17.2 m10.4 m9.9 m

Accounts Receivable

384 k924.5 k1 m

Inventories

1.7 m1.7 m3.4 m5 m

Current Assets

31.1 m24.1 m21.3 m21.7 m

Total Assets

32 m27.2 m23.7 m23.7 m

Accounts Payable

2.7 m1.8 m2.1 m2.6 m

Total Debt

6.1 m

Current Liabilities

3.7 m4.2 m4.2 m11.2 m

Total Liabilities

28.1 m

Additional Paid-in Capital

74.2 m75.5 m88.2 m102.5 m

Retained Earnings

(52.6 m)(69.4 m)(87.4 m)(106.9 m)

Total Equity

21.6 m6 m821 k

Debt to Assets Ratio

0.3 x

Financial Leverage

1.5 x4.5 x28.9 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

17.9 m14 m16.6 m7.8 m9.2 m8.9 m12.5 m7.9 m8.5 m

Accounts Receivable

803.5 k562.2 k351.4 k522.5 k1.2 m944 k826.7 k1.3 m839.9 k

Inventories

1.1 m1.5 m1.9 m2.5 m2.8 m4 m4.2 m4.6 m5.3 m

Current Assets

26.5 m22.6 m31 m27.1 m25.2 m17.4 m29.5 m25.4 m15.7 m

Total Assets

27.9 m25.3 m33.9 m29.8 m27.8 m19.7 m31.7 m27.5 m17.6 m

Accounts Payable

2.3 m2.4 m1.8 m1.6 m2.2 m2.5 m3.3 m2.8 m3.9 m

Current Liabilities

3.8 m4.1 m3.8 m3.2 m4.3 m4.3 m5.1 m9.2 m13 m

Additional Paid-in Capital

74.8 m75.1 m86.5 m87.3 m87.8 m88.7 m102 m102.2 m102.7 m

Retained Earnings

(62.5 m)(65.9 m)(73.1 m)(77.7 m)(82.8 m)(92 m)(98 m)(102.4 m)(113.5 m)

Total Equity

12.3 m9.2 m13.4 m9.5 m4.9 m3.9 m(10.8 m)

Financial Leverage

2.3 x2.7 x2.5 x3.1 x5.7 x8.1 x-1.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(15.5 m)(16.8 m)(18 m)(19.5 m)

Depreciation and Amortization

247.9 k469.8 k469.6 k

Accounts Receivable

(384 k)(540.5 k)(93.6 k)

Inventories

1.7 m(39.7 k)(1.7 m)(1.6 m)

Accounts Payable

2.7 m(937.8 k)308.7 k476.8 k

Cash From Operating Activities

13.6 m(14.7 m)(15.4 m)(18.3 m)

Purchases of PP&E

(2.3 m)(26.1 k)(73.4 k)

Cash From Investing Activities

(4 m)(1.7 m)904.6 k

Cash From Financing Activities

9.8 m10.4 m16.8 m

Interest Paid

785.5 k1.3 m1.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(4 m)(3.4 m)(3.6 m)(4.7 m)(5.1 m)(4.6 m)(6 m)(4.3 m)(6.5 m)

Accounts Receivable

803.5 k562.2 k351.4 k522.5 k1.2 m944 k826.7 k1.3 m839.9 k

Inventories

1.1 m1.5 m1.9 m2.5 m2.8 m4 m4.2 m4.6 m5.3 m

Accounts Payable

2.3 m2.4 m1.8 m1.6 m2.2 m2.5 m3.3 m2.8 m3.9 m
USDY, 2017

Revenue/Employee

28.6 k

Financial Leverage

-1.6 x

ADMA Biologics Market Value History

Traffic Overview of ADMA Biologics

ADMA Biologics News and Updates

BRIEF-Adma Biologics receives CRL from FDA for pending biologics license application

* CRL did not cite any concerns with clinical safety and efficacy data for ri-002 submitted by adma in bla

ADMA Biologics Company Life and Culture

You may also be interested in